Coppell Advisory Solutions’s ImmuCell ICCC Stock Holding History

Coppell Advisory Solutions’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-141	Closed	-$698	–	1348
2023 Q2	$698	Buy	+141	New	+$721	﹤0.01%	1196

Other funds holding ICCC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OMC

Overbrook Management Corp New York $529M AUM 31.5% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Coppell Advisory Solutions's ICCC Position: Q3 2023 in Review

Coppell Advisory Solutions sold out of ImmuCell (ICCC) in Q3 2023, closing a stake of 141 shares — an estimated $698 sold.

Coppell Advisory Solutions first reported a position in ICCC in Q2 2023 and held it in 1 quarter. The position peaked at $698 in Q2 2023. 30 funds tracked by Wall St. Rank hold ICCC as of Q3 2023.

Coppell Advisory Solutions reported no remaining ImmuCell position as of Q3 2023 after selling out during the quarter.
Coppell Advisory Solutions sold 141 ImmuCell shares in Q3 2023, an estimated $698.
Coppell Advisory Solutions first reported a position in ImmuCell in Q2 2023 and held it in 1 quarter.
Coppell Advisory Solutions's ImmuCell position peaked at $698 in Q2 2023.
30 funds tracked by Wall St. Rank held ImmuCell as of Q3 2023.

Based on Coppell Advisory Solutions's 13F filing for Q3 2023, filed 14 Nov 2023.